Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesEuropean approvals for Levocetirizine
Synthon, 05/26/09
Levocetirizine is the active ingredient of UCB's brand product Xyzal. Xyzal is indicated for the treatment of chronic idiopathic urticaria and for relief of symptoms associated with allergic rhinitis. European sales of Xyzal in 2008 were 155 million Euros based on IMS Midas data.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09
FDA Approves Newly Revised Prescribing Information For Azilect Reducing Medication And Food Restrictions
Teva Pharmaceutical Industries, 12/15/09
FDA Advisory Committee Supports Use of Aztreonam for Inhalation Solution for Patients with Cystic Fibrosis
Gilead, 12/14/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Sponsor
Article Search
Sponsor
Sponsor